RecruitingEndometrial Adenocarcinoma
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Eligible age
18+ yrs
Accepts
Women
Locations
31 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Sponsor: Acrivon Therapeutics
You may qualify if…
- ✓ 1. Participant must be able to give signed, written informed consent.
- ✓ 2. Participant must have histologically documented, high-grade endometrial cancer.
- ✓ Arms 1 and 2
- ✓ 1. All high-grade epithelial endometrial histological subtypes are eligible including: endometrioid (all Grade 3), serous, carcinosarcomas, clear-cell carcinoma, and mixed histologies.
- ✓ Note: Subjects with p53 mutant Grade 2 endometrioid cancer are eligible
- ✓ Arms 3 and 4
- ✓ 2. Serous carcinoma or mixed tumors with a majority component of serous carcinoma or carcinosarcoma where the carcinomatous component is serous carcinoma.
- ✓ 3. Treatment History Requirements:
You may not qualify if…
- ✕ 1. Participant with known symptomatic brain metastases requiring \> 10 mg/day of prednisolone (or its equivalent). Participants with previously diagnosed brain metastases are eligible if they have completed their treatment, have recovered from the acute effects of radiation therapy or surgery prior to the start of ACR-368 treatment, fulfill the steroid requirement for these metastases, and are neurologically stable based on central nervous system imaging ≥ 4 weeks after treatment.
- ✕ 2. Participant has mesenchymal tumors of the uterus.
- ✕ 3. Participant has a history of clinically meaningful ascites, defined as history of paracentesis or thoracentesis with therapeutic intent, within 4 weeks of Screening. Subjects with planned therapeutic paracentesis or thoracentesis between Screening and Cycle 1 Day 1 dosing are excluded.
- ✕ 4. Participant had systemic therapy or radiation therapy within 3 weeks prior to the first dose of study drug.
- ✕ 5. Participants has known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection that is considered uncontrolled based on the criteria included in Appendix 2.
- ✕ 6. Participant has a history of clinically meaningful coagulopathy, bleeding diathesis.
- ✕ 7. Participant has cardiovascular disease, defined as:
- ✕ 1. Uncontrolled hypertension defined as blood pressure \> 160/90 mmHg at Screening confirmed by repeat (medication permitted).
Where it's recruiting
Source: ClinicalTrials.gov · NCT05548296 · last updated 2026-08-21